ACCELERATED PUBLICATION
Activation of Glycogen Synthase by Insulin in 3T3-L1 Adipocytes Involves c-Cbl-associating Protein (CAP)-dependent and CAP-independent Signaling Pathways*

Christian A. BaumannDagger §, Matthew J. Brady§, and Alan R. SaltielDagger §||

From the Dagger  Departments of Medicine and Physiology, University of Michigan, Ann Arbor, Michigan 48109 and the § Department of Cell Biology, Pfizer Global Research and Development, Ann Arbor, Michigan 48105

Received for publication, December 4, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In adipose and muscle, insulin stimulates glucose uptake and glycogen synthase activity. Phosphatidylinositol 3-kinase (PI3K) activation is necessary but not sufficient for these metabolic actions of insulin. The insulin-stimulated translocation of phospho-c-Cbl to lipid rafts, via its association with CAP, comprises a second pathway regulating GLUT4 translocation. In 3T3-L1 adipocytes, overexpression of a dominant negative CAP mutant (CAPDelta SH3) completely blocked the insulin-stimulated glucose transport and glycogen synthesis but only partially inhibited glycogen synthase activation. In contrast, CAPDelta SH3 expression did not affect glycogen synthase activation by insulin in the absence of extracellular glucose. Moreover, CAPDelta SH3 has no effect on the PI3K-dependent activation of protein phosphatase-1 or phosphorylation of glycogen synthase kinase-3. These results indicate blockade of the c-Cbl/CAP pathway directly inhibits insulin-stimulated glucose uptake, which results in secondary inhibition of glycogen synthase activation and glycogen synthesis.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Insulin stimulates the storage of glucose as glycogen in muscle and fat through a coordinate increase in glucose uptake and glycogen synthesis (1). Glycogen synthase (GS),1 the rate-limiting enzyme for glycogen synthesis, is regulated by covalent and allosteric modification (2). Insulin promotes the net dephosphorylation of GS through the activation of glycogen-targeted protein-phosphatase-1 (PP1) and inhibition of glycogen synthase kinase-3 (GSK-3). This action of insulin is facilitated by the stimulation of glucose uptake, since the resulting increase in glucose-6-phosphate leads to the allosteric activation of GS and increased susceptibility to PP1-mediated dephosphorylation (3, 4).

The stimulation of glucose disposal by insulin requires the activation of phosphatidylinositol 3-kinase (PI3K), which leads to the increased activity of PIP3-dependent kinases such as Akt and protein kinase C zeta /lambda (5, 6). The PI3K inhibitor wortmannin blocks many of the metabolic actions of insulin, including the effects of the hormone on glucose transport and GS activities (7-9). Moreover, both the inactivation of GSK-3 and the activation of PP1 are blocked by wortmannin (10, 11). However, the activation of PI3K alone is not sufficient for insulin action, since other hormones and adhesion molecules can stimulate PI3K activity without reproducing the metabolic effects of insulin (12, 13). Furthermore, cell-permeable derivatives of PIP3 do not fully mimic the effects of insulin on glucose transport (14). Thus, although the PI3K pathway is necessary, there is at least one additional pathway required for glucose transport regulation by insulin.

The PI3K-independent pathway might involve the tyrosine phosphorylation of the proto-oncogene c-Cbl (15). The phosphorylation of c-Cbl by insulin requires the c-Cbl-associated protein (CAP), an adapter molecule that recruits c-Cbl to the insulin receptor (16). CAP expression correlates with c-Cbl phosphorylation and insulin sensitivity. Moreover, expression of the CAP gene is increased by insulin-sensitizing activators of the nuclear receptor PPARgamma (17). These data suggest a potential link between CAP/Cbl and the metabolic actions of insulin.

Upon phosphorylation, Cbl translocates to a Triton-insoluble lipid raft microdomain (18), where CAP binds to the caveolar protein flotillin (19). In 3T3-L1 adipocytes, expression of a CAP mutant in which the SH3 domains have been deleted (CAPDelta SH3) disrupted the formation of a CAP·flotillin·Cbl complex in lipid rafts, blocked translocation of the insulin-stimulated glucose transporter GLUT4, and inhibited glucose transport, glycogen, and lipid synthesis (19). However, it remained unclear whether CAPDelta SH3 directly blocked the signaling pathways involving GS dephosphorylation that are independent of glucose transport. We demonstrate here that the CAP/Cbl pathway regulates GS activation exclusively through a glucose-dependent mechanism.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- All cell culture reagents were purchased from Life Technologies, Inc. with the exception of serum, which was obtained from Summit Biotechnology (Ft. Collins, CO). Insulin, 2-deoxy-glucose, and differentiation agents were supplied by Sigma. UDP-[U-14C]glucose (308 mCi/mmol) was from by ICN, and D-[14C]glucose (3.4 mCi/mmol) and 2-deoxy-D-[14C]glucose (323 mCi/mmol) were obtained from PerkinElmer Life Sciences. Anti-phospho-Akt (serine 473) and anti-phospo-GSK3 (serine 21/serine 9) antibodies were purchased from New England Biolabs, and horseradish peroxidase goat anti-mouse and goat anti-rabbit IgGs were from Bio-Rad. CAP and CAPDelta SH3 expression vectors were constructed as previously described (16, 19). ECL reagent was purchased from Amersham Pharmacia Biotech, and GF/A filters were supplied by Whatman.

Cell Culture and Experimental Treatment-- 3T3-L1 fibroblasts were maintained and differentiated into adipocytes as previously reported (20). Electroporation of adipocytes was performed as described (21). Prior to insulin stimulation, cells were washed two times with low serum medium (Dulbecco's modified Eagle's medium containing 5 mM glucose, 0.5% fetal bovine serum, 25 mM Hepes (pH 7.4), 100 units/ml penicillin, 100 units/ml streptomycin, and 0.29 mg/ml glutamine) and incubated in the same medium for 3 h.

Enzymatic and Metabolic Assays-- Glucose transport measurements were done as described previously (22) with minor modifications. Briefly, following serum starvation, adipocytes were washed three times with PBS and placed in 0.5 ml/well Krebs-Ringer buffer with 30 mM Hepes (pH 7.4) and 0.5% bovine serum albumin in the absence and presence of 100 nM insulin. After 30 min at 37 °C, 20 µM 2-deoxy-D-[14C]glucose (~20 cpm/pmol) was added to all wells. After 5 min at room temperature, the assay was terminated by the adding 50 µl of 200 mM 2-deoxyglucose and washing the cells 3 times with PBS on ice. Adipocytes were collected in 0.5 ml of distilled water. 10 µl of the cell suspension was retained to determine protein concentration and the remainder was subject to scintillation counting.

Glycogen synthase assays were performed as described (22). In some experiments, the cells were washed and incubated in glucose-free, low serum media immediately prior to insulin treatment. Measurement of PP1 activity was performed as described previously (23), with 1-2 µg of cell extract assayed for 2 min at 30 °C. Glycogen synthesis rate was measured in 6-well dishes as reported (22). Briefly, cells were treated in the absence and presence of 100 nM insulin for 15 min, and then 1 µCi of [14C]glucose (20 cpm/pmol) was added to all wells. After 45 min, cells were washed on ice with PBS, and glycogen was precipitated with 30% potassium hydroxide and quantitated by scintillation counting.

Other Procedures-- Immunoblotting (22) and immunoprecipitations (15) were performed as described previously. Protein measurements were determined by the method of Bradford.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

CAPDelta SH3 Expression Blocks Glucose Uptake and Glycogen Synthesis in 3T3-L1 Adipocytes-- CAPDelta SH3 overexpression in 3T3-L1 adipocytes significantly inhibits the translocation of the insulin-stimulated glucose transporter GLUT4 to the plasma membrane, without affecting PI3K-dependent signals (19). To explore the implications of this result in more detail, we examined the effects of CAPDelta SH3 expression on glucose uptake and glycogen synthesis over a range of insulin concentrations. In control LacZ-transfected 3T3-L1 adipocytes, insulin produced a 15-fold increase in glucose transport (Fig. 1A) and a 10-fold increase in glycogen synthesis (Fig. 1B). Overexpression of CAPDelta SH3 decreased maximal glucose uptake by 40-50% (Fig. 1A). The construct blocked the responsiveness to insulin without effecting the EC50 for the hormone. Not surprisingly, CAPDelta SH3 expression also blocked insulin-stimulated glycogen synthesis (Fig. 1B), which is dependent on increased glucose uptake under these conditions. Extrapolating for an average 50% transfection efficiency (data not shown), these results demonstrate that expression of CAPDelta SH3 in 3T3-L1 adipocytes produces a nearly complete inhibition of insulin-stimulated glucose uptake and glycogen synthesis.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   CAPDelta SH3 expression inhibits insulin-stimulated glucose transport and glycogen synthesis. 3T3-L1 adipocytes were electroporated with either LacZ or constructs, replated, and allowed to recover for 36 h. After a 3-h incubation in low serum media containing 5 mM glucose, basal and insulin-stimulated glucose transport (A) and glycogen synthesis (B) rates were determined as described under "Experimental Procedures." Results are the average of three independent experiments, each performed in triplicate. *, significant difference from LacZ control, p < 0.01, n = 3 by Student's t test. **, significant difference from LacZ control, p < 0.05, n = 3, by Student's t test.

Inhibition of GS Activation by CAPDelta SH3 Is a Result of Reduced Glucose Uptake-- We next examined the effects of CAPDelta SH3 expression on the regulation of GS activity by insulin. Electroporation of 3T3-L1 adipocytes with CAPDelta SH3 resulted in a 30% decrease in the activation of GS by insulin, compared with both LacZ- and CAP-expressing cells (Fig. 2A). In these experiments the electroporation efficiency was ~50-60% (data not shown), indicating that CAPDelta SH3 overexpression reduced GS activation by half. Previous studies in 3T3-L1 adipocytes indicated that removal of extracellular glucose also decreased the insulin-stimulated GS activity by 40-50% (20), suggesting that the effect of CAPDelta SH3 on GS activation may be secondary to inhibition of glucose transport. To evaluate this possibility directly, the electroporated adipocytes were incubated in glucose-free medium during the insulin treatment, and GS activity was assayed in vitro. Removal of extracellular glucose decreased insulin-stimulated GS activity by 40% in LacZ- and CAP-expressing cells (Fig. 2B; compare with Fig. 2A). However, CAPDelta SH3 expression had no further inhibitory effect on GS activation by insulin. Thus, the glucose-independent pathway that mediates the dephosphorylation and subsequent activation of GS by insulin appears not to involve the CAP/Cbl pathway.



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 2.   CAPDelta SH3 inhibits the glucose-dependent activation of glycogen synthase. 3T3-L1 adipocytes were electroporated with the indicated constructs and allowed to recover for 36 h. A, after a 3-h incubation in low serum media containing 5 mM glucose, cells were treated in the absence and presence of 100 nM insulin for 15 min. Cells were washed on ice with PBS and harvested, and GS activity was measured in vitro in the absence and presence of 10 mM glucose-6-phosphate (G6P). B, after a 3-h serum starvation, all wells were washed twice and incubated in low serum media lacking glucose immediately prior to the insulin treatment. Results are an average of three independent experiments done in duplicate. *, significant difference from LacZ control, p < 0.01, n = 3 by Student's t test.

The PI3K inhibitor wortmannin completely blocked the regulation of GS, PP1, and GSK-3 by insulin (10, 11). In contrast, pretreatment of 3T3-L1 adipocytes with 200 nM wortmannin did not significantly change the insulin-stimulated tyrosine phosphorylation of c-Cbl (Fig. 3A). However, wortmannin pretreatment of transfected cells incubated in glucose-free media completely blocked the residual activation of GS by insulin (Fig. 3B). Thus, a PI3K-dependent pathway is likely to trigger the glucose-independent activation of GS.



View larger version (25K):
[in this window]
[in a new window]
 
Fig. 3.   Wortmannin inhibits the glucose-independent activation of glycogen synthase. A, 3T3-L1 adipocytes were serum starved for 3 h and then preincubated for 30 min with either 200 nM wortmannin (Wort.) or an equal volume of Me2SO (DMSO). Cells were stimulated for 2 min in the absence or presence of 100 nM insulin. Cells were harvested, and anti-c-Cbl immunoprecipitations (I.P.) were preformed. Samples were then analyzed by anti-phosphotyrosine and c-Cbl immunoblotting (I.B.). B, 3T3-L1 adipocytes were electroporated with the indicated constructs and treated as in Fig. 2B, except the indicated wells were pretreated for 30 min with 200 nM wortmannin (Wort). After a 15 min treatment with 100 nM insulin (Ins), glycogen synthase activity was determined in vitro. Results are representative of three independent experiments (A) or the average of three independent experiments performed in duplicate (B). *, significant difference from LacZ control, p < 0.01, n = 3 by Student's t test.

CAPDelta SH3 Has No Effect on the Regulation of PP1 and GSK-3 by Insulin-- Insulin promotes the activation of GS by decreasing the phosphorylation state of the enzyme. Both the activation of glycogen-targeted PP1 and the inactivation of GSK-3 have been proposed to mediate this effect of the hormone (5). We next examined the effect of CAPDelta SH3 expression on the regulation of these enzymes by insulin. Electroporation of LacZ, CAP, or CAPDelta SH3 into 3T3-L1 adipocytes had no effect on the insulin-stimulated phosphorylation of GSK3 (Fig. 4A), which results in enzymatic inactivation (24). Insulin treatment of LacZ-electroporated cells also caused a 50% increase in PP1 activity (Fig. 4B). Overexpression of either CAP or CAPDelta SH3 had no effect on PP1 activation by insulin in 3T3-L1 adipocytes (Fig. 4B). These results cumulatively indicate that the CAP/Cbl pathway is not necessary for the insulin-mediated regulation of enzymes that covalently modify GS.



View larger version (25K):
[in this window]
[in a new window]
 
Fig. 4.   Regulation of GSK-3 and PP1 by insulin is unaffected by expression of CAPDelta SH3. 3T3-L1 adipocytes were electroporated with the indicated constructs. After a 36-h recovery, cells were treated for 15 min in the absence and presence of 100 nM insulin. A, anti-phospho-GSK-3 immunoblotting. 40 µg of cellular lysates were separated by SDS-PAGE, transferred to nitrocellulose, and probed with an anti-phospho-GSK-3 antibody. Antibody binding was visualized with ECL and autoradiography. Results are representative of three independent experiments. B, PP1 activity. After treatment, cells were harvested, and PP1 activity was measured in vitro using 32P-labeled phosphorylase as substrate. Results are representative of four independent experiments, each performed in triplicate.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Insulin stimulates glycogen synthesis in muscle and fat by a coordinate increase in GLUT4 vesicle translocation and covalent modification of glycogen metabolizing enzymes (1). Insulin promotes the dephosphorylation of glycogen synthase and phosphorylase, resulting in enzymatic activation and inactivation, respectively. Both phosphatase activation and kinase inactivation contribute to the dephosphorylation of both proteins in response to insulin. Additionally, increased glucose-6-phosphate levels allosterically activate GS, overriding inhibition caused by phosphorylation (2). Finally, glucose metabolites induce the translocation of cytosolic GS to glycogen-containing fractions in primary hepatocytes (25), skeletal muscle (26), and 3T3-L1 adipocytes (20). Insulin therefore activates GS through covalent modification, allosteric activation, and enzymatic translocation. However, the complex interplay between insulin signaling cascades, elevated levels of glucose, and its metabolites and glycogen stores in the regulation of GS activity and glycogen synthesis rates remains unclear.

The activation of PI3K and downstream serine/threonine kinases plays an important role in the hormonal regulation of glucose uptake and storage. Pharmacological inhibition of PI3K blocked the stimulation of glucose transport (7) and the enzymes involved in glycogen metabolism, such as GS, PP1, and GSK-3 (10, 11). Further, overexpression of PI3K or downstream enzymatic effectors in cells partially increased glucose uptake (27, 28). However, PI3K activation is not sufficient to mediate changes in glucose metabolism produced by insulin (12-14), implicating a second signaling pathway.

The PI3K-independent arm of insulin action may result from the phosphorylation of c-Cbl via its association with CAP. Insulin stimulated c-Cbl phosphorylation and translocation of the Cbl·CAP complex to lipid rafts, where CAP directly bound flotillin (15, 18, 19). The insulin-dependent localization of phospho-Cbl to subdomains of the plasma membrane resulted in the generation of signaling pathways involved in GLUT4 translocation. In 3T3-L1 adipocytes, overexpression of the dominant negative CAP mutant, CAPDelta SH3, specifically blocked the insulin-mediated translocation of phospho-Cbl into lipid rafts and completely inhibited insulin-stimulated GLUT4 translocation (19). Interestingly, the insulin-mediated phosphorylation and translocation of Cbl were not blocked by PI3K inhibitors (Fig. 3A, data not shown), indicating that the Cbl·CAP·flotillin axis may comprise the PI3K-independent pathway regulating glucose transport.

Overexpression of the dominant negative mutant CAPDelta SH3 completely blocked insulin-stimulated glucose transport and glycogen synthesis in 3T3-L1 adipocytes, correcting for transfection efficiency (Fig. 1, A and B). Further, CAPDelta SH3 overexpression also reduced insulin-mediated GS activation by 50% (Fig. 2A). Interestingly, this effect was solely the result of reduced glucose uptake, because CAPDelta SH3 did not block GS activation in the absence of extracellular glucose (Figs. 2B and 3B). Moreover, the inhibition of GSK-3 and activation of PP1 by insulin were unaffected by CAPDelta SH3 expression (Fig. 4, A and B), whereas the glucose-independent activation of GS by insulin was completely suppressed by the PI3K inhibitor wortmannin (Fig. 3B).

In primary adipocytes, insulin and glucose synergistically promote the dephosphorylation and activation of GS (29). Removal of extracellular glucose decreases insulin-stimulated GS activation by 40% in 3T3-L1 adipocytes (Fig. 2B) (20). Similarly, blockade of glucose transport by CAPDelta SH3 overexpression caused a 50% reduction in GS activation by insulin. However, the regulation of GSK-3 and PP1 by insulin was unaffected by CAPDelta SH3, indicating that these enzymes may constitute the other 50% of GS activation. In agreement, the PI3K inhibitor wortmannin, which completely blocks the effects of insulin on GSK-3 and PP1 activities (10, 11), also blocked the glucose-independent activation of GS (Fig. 3B). Cumulatively, these results indicate that in 3T3-L1 adipocytes, insulin utilizes glucose-dependent and independent pathways to regulate GS activity. In parallel, insulin initiates PI3K-dependent and -independent signaling pathways to mobilize GLUT4 translocation. Blockade of the PI3K-independent, CAP/Cbl-dependent insulin pathway through CAPDelta SH3 expression inhibits GLUT4 translocation and the glucose-dependent component of GS activation by insulin. In contrast, pharmacological inactivation of PI3K blocks both insulin-mediated stimulation of glucose transport and regulation of PP1 and GSK-3 activities, resulting in a complete inhibition of GS activation. Whether insulin also utilizes a PI3K-independent pathway to regulate PP1 and GSK-3 activities is presently under investigation.


    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

These authors contributed equally to this work.

|| To whom correspondence should be addressed: University of Michigan Medical Center, MSRB I, Rm. 4520, 1150 West Medical Center Dr., Ann Arbor, MI 48109. Tel.: 734-615-9787; Fax: 734-936-2888; E-mail: saltiel@umich.edu.

Published, JBC Papers in Press, January 12, 2001, DOI 10.1074/jbc.C000856200


    ABBREVIATIONS

The abbreviations used are: GS, glycogen synthase; PI3K, phosphatidylinositol 3-kinase; PP1, type 1 protein phosphatase; GSK-3, glycogen synthase kinase-3; CAP, c-Cbl-associating protein; PBS, phosphate-buffered saline; LacZ, beta -galactosidase; PIP3, phosphatidylinositol 1,4,5-trisphosphate; SH3, Src 3 homology.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Brady, M. J., Pessin, J. E., and Saltiel, A. R. (1999) Trends Endocrinol. Metab. 10, 408-413[CrossRef][Medline] [Order article via Infotrieve]
2. Lawrence, J. C., Jr., and Roach, P. J. (1997) Diabetes 46, 541-547[Abstract]
3. Lawrence, J. C., Jr., and James, C. (1984) J. Biol. Chem. 259, 7975-7982[Abstract/Free Full Text]
4. Cadefau, J., Bollen, M., and Stalmans, W. (1997) Biochem. J. 322, 745-750[Medline] [Order article via Infotrieve]
5. Cohen, P., Alessi, D. R., and Cross, D. A. (1997) FEBS Lett. 410, 3-10[CrossRef][Medline] [Order article via Infotrieve]
6. Standaert, M. L., Galloway, L., Karnam, P., Bandyopadhyay, G., Moscat, J., and Farese, R. V. (1997) J. Biol. Chem. 272, 30075-30082[Abstract/Free Full Text]
7. Czech, M. P., and Corvera, S. (1999) J. Biol. Chem. 274, 1865-1868[Free Full Text]
8. Shepherd, P. R., Nave, B. T., and Siddle, K. (1995) Biochem. J. 305, 25-28[Medline] [Order article via Infotrieve]
9. Sakaue, H., Hara, K., Noguchi, T., Matozaki, T., Kotani, K., Ogawa, W., Yonezawa, K., Waterfield, M. D., and Kasuga, M. (1995) J. Biol. Chem. 270, 11304-11309[Abstract/Free Full Text]
10. Hurel, S. J., Rochford, J. J., Borthwick, A. C., Wells, A. M., Vandenheede, J. R., Turnbull, D. M., and Yeaman, S. J. (1996) Biochem. J. 320, 871-877[Medline] [Order article via Infotrieve]
11. Brady, M. J., Bourbonais, F. J., and Saltiel, A. R. (1998) J. Biol. Chem. 273, 14063-14066[Abstract/Free Full Text]
12. Wiese, R. J., Mastick, C. C., Lazar, D. F., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 3442-3446[Abstract/Free Full Text]
13. Guilherme, A., and Czech, M. P. (1998) J. Biol. Chem. 273, 33119-33122[Abstract/Free Full Text]
14. Jiang, T., Sweeney, G., Rudolf, M. T., Klip, A., Traynor-Kaplan, A., and Tsien, R. Y. (1998) J. Biol. Chem. 273, 11017-11024[Abstract/Free Full Text]
15. Ribon, V., and Saltiel, A. R. (1997) Biochem. J. 324, 839-845[Medline] [Order article via Infotrieve]
16. Ribon, V., Printen, J. A., Hoffman, N. G., Kay, B. K., and Saltiel, A. R. (1998) Mol. Cell. Biol. 18, 872-879[Abstract/Free Full Text]
17. Ribon, V., Johnson, J. H., Camp, H. S., and Saltiel, A. R. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 14751-14756[Abstract/Free Full Text]
18. Mastick, C. C., and Saltiel, A. R. (1997) J. Biol. Chem. 272, 20706-20714[Abstract/Free Full Text]
19. Baumann, C. A., Ribon, V., Kanzaki, M., Thurmond, D. C., Mora, S., Shigematsu, S., Bickel, P. E., Pessin, J. E., and Saltiel, A. R. (2000) Nature 407, 202-207[CrossRef][Medline] [Order article via Infotrieve]
20. Brady, M. J., Kartha, P. M., Aysola, A. A., and Saltiel, A. R. (1999) J. Biol. Chem. 274, 27497-27504[Abstract/Free Full Text]
21. Min, J., Okada, S., Kanzaki, M., Elmendorf, J. S., Coker, K. J., Ceresa, B. P., Syu, L. J., Noda, Y., Saltiel, A. R., and Pessin, J. E. (1999) Mol. Cell. 3, 751-760[CrossRef][Medline] [Order article via Infotrieve]
22. Lazar, D. F., Wiese, R. J., Brady, M. J., Mastick, C. C., Waters, S. B., Yamauchi, K., Pessin, J. E., Cuatrecasas, P., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 20801-20807[Abstract/Free Full Text]
23. Brady, M. J., Nairn, A. C., and Saltiel, A. R. (1997) J. Biol. Chem. 272, 29698-29703[Abstract/Free Full Text]
24. Welsh, G. I., and Proud, C. G. (1993) Biochem. J. 294, 625-629[Medline] [Order article via Infotrieve]
25. Fernandez-Novell, J. M., Arino, J., Vilaro, S., Bellido, D., and Guinovart, J. J. (1992) Biochem. J. 288, 497-501[Medline] [Order article via Infotrieve]
26. Nielsen, J. N., Derave, W., Kristiansen, S., Ralston, E., Ploug, T., and Richter, E. A. (2001) J. Physiol., in press
27. Tanti, J. F., Gremeaux, T., Grillo, S., Calleja, V., Klippel, A., Williams, L. T., Van Obberghen, E., and Le Marchand-Brustel, Y. (1996) J. Biol. Chem. 271, 25227-25232[Abstract/Free Full Text]
28. Cong, L. N., Chen, H., Li, Y., Zhou, L., McGibbon, M. A., Taylor, S. I., and Quon, M. J. (1997) Mol. Endocrinol. 11, 1881-1890[Abstract/Free Full Text]
29. Lawrence, J. C., Jr., and Larner, J. (1978) J. Biol. Chem. 253, 2104-2113[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.